文献速递胸部肿瘤

Ifinatamab deruxtecan 治疗广泛期小细胞肺癌:II 期 IDeate-Lung01 试验主要分析

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial.
PubMed 文献 · J Clin Oncol · 2025-10-14

IDeate-Lung01 是一项 II 期试验,评估 B7-H3 靶向抗体偶联药物 ifinatamab deruxtecan(I-DXd)在经治广泛期小细胞肺癌(ES-SCLC)中的疗效与安全性。183 例患者入组,12 mg/kg 组确认客观缓解率(ORR)为 48.2%,中位缓解持续时间 5.3 个月,中位无进展生存期 4.9 个月,9 个月总生存估计 59.1%。安全性与此前报告一致,未发现新信号。

要点

  • I-DXd 12 mg/kg 每 3 周一次在经治 ES-SCLC 中确认 ORR 达 48.2%。
  • 中位 PFS 4.9 个月,9 个月 OS 估计 59.1%,中位 DOR 5.3 个月。
  • 治疗相关间质性肺病发生率为 12.4%,≥3 级为 4.4%。

核心结论

  • I-DXd 12 mg/kg 每 3 周一次在经治 ES-SCLC 中显示出有前景的疗效。
  • 安全性特征与此前报告一致,未发现新的安全信号。

研究设计与样本

  • II 期 IDeate-Lung01 试验,第一部分为剂量优化(随机接受 I-DXd 8 或 12 mg/kg 静脉给药,每 3 周一次),第二部分为扩展(接受 I-DXd 12 mg/kg)。
  • 共 183 例经治 ES-SCLC 患者接受 I-DXd:第一部分 88 例(8 mg/kg 组 46 例,12 mg/kg 组 42 例),第二部分 95 例。
  • 主要终点为盲法独立中心评审按 RECIST 1.1 评估的客观缓解率(ORR)。
  • 患者既往中位治疗线数为 2 线。

主要发现

  • 第一部分与第二部分合计 12 mg/kg 组(n=137)的确认 ORR 为 48.2%(95% CI,39.6 至 56.9)。
  • 12 mg/kg 组中位缓解持续时间为 5.3(95% CI,4.0 至 6.5)个月,中位起效时间为 1.4(范围,1.0-8.1)个月。
  • 12 mg/kg 组中位无进展生存期为 4.9(95% CI,4.2 至 5.5)个月,9 个月总生存估计为 59.1%。
  • 任何级别治疗相关不良事件(TRAE)发生率为 89.8%(≥3 级,36.5%)。
  • 最常见的 TRAE 为恶心(43.1%)、贫血(34.3%)和中性粒细胞减少(34.3%)。

关键数值与推荐

  • 12 mg/kg 组确认 ORR 48.2%(95% CI,39.6 至 56.9),中位 DOR 5.3(95% CI,4.0 至 6.5)个月。
  • 12 mg/kg 组中位 PFS 4.9(95% CI,4.2 至 5.5)个月,9 个月 OS 估计 59.1%。
  • 任何级别 TRAE 89.8%,≥3 级 TRAE 36.5%。
  • 导致治疗终止的 TRAE 为 9.5%,导致死亡的 TRAE 为 4.4%。
  • 经 ILD 裁定委员会确定的治疗相关间质性肺病(ILD)为 12.4%(≥3 级,4.4%)。

临床怎么用

  • I-DXd 12 mg/kg 每 3 周一次可作为经治 ES-SCLC 的潜在治疗选择。
  • 用药期间需关注恶心、贫血、中性粒细胞减少及间质性肺病等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment options for patients with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) are limited. This phase II trial evaluated the efficacy and safety of ifinatamab deruxtecan (I-DXd), a B7 homolog 3-directed antibody-drug conjugate, in patients with previously treated ES-SCLC. METHODS: Patients were randomly assigned to receive I-DXd 8 or 12 mg/kg intravenously once every 3 weeks in part 1 (dose optimization) and received I-DXd 12 mg/kg in part 2 (extension). The primary end point was objective response rate (ORR) by blinded independent central review per RECIST, version 1.1. RESULTS: Overall, 183 patients received I-DXd: 88 in part 1 (8 mg/kg, n = 46; 12 mg/kg, n = 42) and 95 in part 2. The median number of previous lines of treatment was two. In the total 12-mg/kg group from parts 1 and 2 (n = 137), the confirmed ORR was 48.2% (95% CI, 39.6 to 56.9), median duration of response was 5.3 (95% CI, 4.0 to 6.5) months, median time to response was 1.4 (range, 1.0-8.1) months, median progression-free survival was 4.9 (95% CI, 4.2 to 5.5) months, and the 9-month overall survival estimate was 59.1%. Any-grade treatment-related adverse events (TRAEs) occurred in 89.8% of patients (grade ≥3, 36.5%). The most common TRAEs were nausea (43.1%), anemia (34.3%), and neutropenia (34.3%). TRAEs associated with treatment discontinuation and death were reported in 9.5% and 4.4% of patients, respectively. Treatment-related interstitial lung disease (ILD) as determined by the ILD adjudication committee was reported in 12.4% of patients (grade ≥3, 4.4%). CONCLUSION: I-DXd 12 mg/kg once every 3 weeks showed promising efficacy in patients with previously treated ES-SCLC. The observed safety profile was consistent with previous reports, with no new safety signals identified.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rudin CM, Johnson ML, Paz-Ares L, et al. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. J Clin Oncol. 2025. PMID: 41086386. doi:10.1200/JCO-25-02142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。